Alfasigma USA, Inc. the United States distributor of tegaserod, brand name Zelnorm, which is a prescription medication for some women with IBS with constipation (IBS-C), has announced that as of June 30, 2022, it is no longer providing this medication. Alfasigma’s press release states that this decision is not due to a recall or any concerns about safety or effectiveness, but is “strictly a business decision.” Zelnorm may still be available to patients for some time until existing supplies are exhausted. Alfasigma encourages individuals currently taking Zelnorm to speak to their physicians regarding alternatives.
This announcement does not appear to affect Zelnorm availability in other countries where it is currently approved for use.The Alfasigma press release is linked below. IBS Impact has no further information at this time, but will update if any is received. We encourage affected individuals to consult their prescribing doctors for further guidance.
Press Release on Notice of Withdrawal.pdf (myzelnorm.com)
Posted July 2022